Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG(4) response

BACKGROUND: BM32, a grass pollen allergy vaccine containing four recombinant fusion proteins consisting of hepatitis B-derived PreS and hypoallergenic peptides from the major timothy grass pollen allergens adsorbed on aluminium hydroxide has been shown to be safe and to improve clinical symptoms of...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :EBioMedicine
Главные авторы: Eckl-Dorna, Julia, Weber, Milena, Stanek, Victoria, Linhart, Birgit, Ristl, Robin, Waltl, Eva E., Villazala-Merino, Sergio, Hummel, Andrea, Focke-Tejkl, Margarete, Froeschel, Renate, Neubauer, Angela, Henning, Rainer, Perkmann, Thomas, Valenta, Rudolf, Niederberger, Verena
Формат: Artigo
Язык:Inglês
Опубликовано: Elsevier 2019
Предметы:
Research paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6921329/
https://ncbi.nlm.nih.gov/pubmed/31786130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.11.006
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы